Javier De Castro-Carpeño

25PUBLICATIONS
213CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jul 28, 2026
Real-World Insights into Stage I-III Non-Small Cell Lung Cancer in Spain in the Pre-Immunotherapy Era Using AI Techniques: The IntellyLUNG Study.

|Jul 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

|Apr 13, 2026
Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Federico Rojo, Enriqueta Felip, Oscar Juan Vidal

|Mar 10, 2026
Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.

Belén Sierra-Rodero, Ángeles Gil-González, Marta Molina-Alejandre

|Mar 06, 2026
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.

Zofia Piotrowska, Myung-Ju Ahn, Pei Jye Voon

|Jan 15, 2026
Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer.

Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal

Pageof 5

Frequent Collaborators

8 joint publications

Ernest Nadal

8 joint publications

Mariano Provencio Pulla

6 joint publications

Alberto Cruz-Bermúdez

6 joint publications

Amelia Insa Molla